These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29627370)

  • 1. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers.
    Zhou G; Latchoumanin O; Hebbard L; Duan W; Liddle C; George J; Qiao L
    Adv Drug Deliv Rev; 2018 Sep; 134():107-121. PubMed ID: 29627370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine.
    Xiang D; Shigdar S; Qiao G; Wang T; Kouzani AZ; Zhou SF; Kong L; Li Y; Pu C; Duan W
    Theranostics; 2015; 5(1):23-42. PubMed ID: 25553096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic aptamers: developmental potential as anticancer drugs.
    Lee JW; Kim HJ; Heo K
    BMB Rep; 2015 Apr; 48(4):234-7. PubMed ID: 25560701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.
    Milane L; Ganesh S; Shah S; Duan ZF; Amiji M
    J Control Release; 2011 Oct; 155(2):237-47. PubMed ID: 21497176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression.
    Nobili S; Landini I; Mazzei T; Mini E
    Med Res Rev; 2012 Nov; 32(6):1220-62. PubMed ID: 21374643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological strategies for overcoming multidrug resistance.
    Nobili S; Landini I; Giglioni B; Mini E
    Curr Drug Targets; 2006 Jul; 7(7):861-79. PubMed ID: 16842217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy.
    Li X; Zhao Q; Qiu L
    J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR.
    Mohammad IS; He W; Yin L
    Biomed Pharmacother; 2018 Apr; 100():335-348. PubMed ID: 29453043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aptamer applications for targeted cancer therapy.
    Barbas AS; Mi J; Clary BM; White RR
    Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell-targeted, size-photocontrollable, nuclear-uptake nanodrug delivery system for drug-resistant cancer therapy.
    Qiu L; Chen T; Öçsoy I; Yasun E; Wu C; Zhu G; You M; Han D; Jiang J; Yu R; Tan W
    Nano Lett; 2015 Jan; 15(1):457-63. PubMed ID: 25479133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents.
    Kim M; Kim DM; Kim KS; Jung W; Kim DE
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development and testing of aptamers for cancer.
    Barbas AS; White RR
    Curr Opin Investig Drugs; 2009 Jun; 10(6):572-8. PubMed ID: 19513946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies.
    Wang M; Chen W; Chen J; Yuan S; Hu J; Han B; Huang Y; Zhou W
    Eur J Med Chem; 2021 Aug; 220():113487. PubMed ID: 33933752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aptamer-guided nanomedicines for anticancer drug delivery.
    Alshaer W; Hillaireau H; Fattal E
    Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles.
    Zhang Q; Li F
    Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer.
    Dinic J; Podolski-Renic A; Stankovic T; Bankovic J; Pesic M
    Curr Pharm Des; 2015; 21(38):5589-604. PubMed ID: 26429711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.